Fibrotic diseases treatment market seen reaching $58.1 billion by 2035

Market Research Future projects the global fibrotic diseases treatment market will more than double to $58.1 billion by 2035 from $27.4 billion in 2025, driven by rising disease burden, more clinical readouts and expanding metabolic liver disease care. North America leads revenue now, while Asia-Pacific is expected to grow fastest through the forecast period.

Why it matters: - The fibrotic diseases treatment market is moving from a narrow specialty area into a larger, more durable revenue pool. - Growth is being driven by more diagnosed patients, earlier detection and more drugs reaching late-stage development. - The market could matter more for payers and health systems as fibrosis care shifts from symptom management toward disease-modifying treatment.

What happened: - Market Research Future projected the global fibrotic diseases treatment market will rise from USD 27.4 billion in 2025 to USD 58.1 billion by 2035. - The forecast implies a 7.8% compound annual growth rate from 2026 to 2035. - The market was valued at USD 29.5 billion in 2026 under the report’s forecast path. - North America held 41.5% of 2025 revenue. - Asia-Pacific was forecast to be the fastest-growing region at a 9.4% CAGR through 2035. - The report was published Sept. 17, 2026.

The details: - Rising disease burden is a core growth driver. - The report cites about 50,000 new idiopathic pulmonary fibrosis diagnoses annually in the United States. - Specialist-care prevalence in Europe was measured at 36.0 per 100,000 population. - The World Health Organization attributes more than 1.3 million deaths a year to cirrhosis. - ClinicalTrials.gov listed 214 interventional fibrosis studies in active recruitment in Q4 2025, up from 118 five years earlier. - About 38% of adults in high-income economies have steatotic liver disease, and 5% to 7% of those patients progress to significant fibrosis. - Nintedanib and pirfenidone are reimbursed in 47 countries. - The U.S. FDA’s orphan-drug incentive framework has helped keep idiopathic pulmonary fibrosis programs viable despite trial attrition above 60%. - The European Commission’s Innovative Health Initiative committed EUR 2.4 billion across 2021-2027 to chronic organ-injury research. - Global venture and corporate investment in fibrosis-focused biotechs topped USD 4.1 billion from 2023 to 2025. - About 38% of that capital went to hepatic indications. - Elastography and blood-based panels cut fibrosis staging costs by an estimated 62% versus biopsy. - NHS England’s community liver-health pathway screened more than 400,000 at-risk adults from 2023 to 2025 and found advanced fibrosis in about 4.8%. - Medication was the largest treatment segment in 2025 with a 58.2% share. - Organ transplantation was valued at USD 5.9 billion in 2025. - Oxygen therapy was the fastest-growing treatment line at a 6.1% CAGR from 2026 to 2035. - Idiopathic pulmonary fibrosis was the largest application in 2025 with a 38.4% share. - Hepatic cirrhosis was valued at USD 7.6 billion in 2025. - Renal fibrosis was the fastest-growing application at a 9.1% CAGR from 2026 to 2035. - Hospitals led end-user revenue with a 62.5% share in 2025. - Academic and research institutes accounted for USD 6.5 billion in 2025. - North America’s market was led by the United States, which generated about 86.4% of regional revenue. - Europe’s market was led by Germany, which held 23.8% of regional revenue. - China held 38.6% of Asia-Pacific revenue. - India was the fastest-growing Asia-Pacific market at an 11.2% CAGR. - Brazil anchored South America with 58.3% of regional revenue. - Saudi Arabia held 31.5% of Middle East and Africa revenue.

Between the lines: - The report suggests fibrosis is becoming a broader commercial category because diagnostics are pulling patients into care earlier. - Hepatic fibrosis is emerging as a major growth engine because screening programs are expanding the addressable population before severe disease develops. - The competitive market remains concentrated, but not enough to shut out newer entrants in liver and kidney fibrosis. - The top five players held about 47% of 2025 revenue, leaving room for contestable segments. - Combination regimens, biomarker-based trials and machine-learning staging tools could reshape treatment and trial economics over the next decade. - Boehringer Ingelheim reported positive Phase III results for nerandomilast in September 2024, strengthening the case for a new pulmonary mechanism. - Madrigal Pharmaceuticals secured accelerated FDA approval for resmetirom in March 2024, creating the first reimbursed pharmacological pathway for hepatic fibrosis. - Gilead Sciences entered a hepatic antifibrotic licensing deal in April 2025, showing larger drugmakers are still moving into the space.

What's next: - The report expects more readouts from fibrosis drug pipelines through 2035. - Eight sponsors are now running Phase II trials that combine an established antifibrotic backbone with an integrin or autotaxin inhibitor. - Asia-Pacific access should keep widening as reimbursement expands in China and generic manufacturing scales in India. - The report says first human proof-of-concept studies for reversal approaches could read out before 2030. - By 2035, fibrosis care is expected to move further from symptom control toward disease modification and possible reversal.

The bottom line: - Fibrosis treatment is becoming a larger global market because more patients are being found earlier and more therapies are nearing commercial reality.